ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa

This ALK‐positive anaplastic large cell lymphoma (ALCL) case highlights the importance of considering ALCL in the setting of iatrogenic immunosuppression in hidradenitis suppurativa patients. Diagnosis of ALCL can be challenging in situations with very low viability/cellularity, negative CD3 and/or...

Descripción completa

Detalles Bibliográficos
Autores principales: Craig, Alexander, Wen, Kwun Wah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090933/
https://www.ncbi.nlm.nih.gov/pubmed/37064740
http://dx.doi.org/10.1002/ccr3.7156
_version_ 1785023060405911552
author Craig, Alexander
Wen, Kwun Wah
author_facet Craig, Alexander
Wen, Kwun Wah
author_sort Craig, Alexander
collection PubMed
description This ALK‐positive anaplastic large cell lymphoma (ALCL) case highlights the importance of considering ALCL in the setting of iatrogenic immunosuppression in hidradenitis suppurativa patients. Diagnosis of ALCL can be challenging in situations with very low viability/cellularity, negative CD3 and/or other T‐cell markers, and immunosuppression.
format Online
Article
Text
id pubmed-10090933
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100909332023-04-13 ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa Craig, Alexander Wen, Kwun Wah Clin Case Rep Case Images This ALK‐positive anaplastic large cell lymphoma (ALCL) case highlights the importance of considering ALCL in the setting of iatrogenic immunosuppression in hidradenitis suppurativa patients. Diagnosis of ALCL can be challenging in situations with very low viability/cellularity, negative CD3 and/or other T‐cell markers, and immunosuppression. John Wiley and Sons Inc. 2023-04-12 /pmc/articles/PMC10090933/ /pubmed/37064740 http://dx.doi.org/10.1002/ccr3.7156 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Images
Craig, Alexander
Wen, Kwun Wah
ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title_full ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title_fullStr ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title_full_unstemmed ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title_short ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
title_sort alk+ alcl in the setting of adalimumab‐related hidradenitis suppurativa
topic Case Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090933/
https://www.ncbi.nlm.nih.gov/pubmed/37064740
http://dx.doi.org/10.1002/ccr3.7156
work_keys_str_mv AT craigalexander alkalclinthesettingofadalimumabrelatedhidradenitissuppurativa
AT wenkwunwah alkalclinthesettingofadalimumabrelatedhidradenitissuppurativa

Ejemplares similares